Brokerages Expect Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS
Equities analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to announce earnings per share (EPS) of $0.25 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.27 and the lowest estimate coming in at $0.23. Sucampo Pharmaceuticals posted earnings per share of $0.28 in the same quarter last year, which suggests a negative year over year growth rate of 10.7%. The firm is expected to issue its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.01 per share for the current fiscal year, with EPS estimates ranging from $0.98 to $1.04. For the next year, analysts expect that the business will report earnings of $1.06 per share, with EPS estimates ranging from $0.98 to $1.14. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.22 by $0.06. The company had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. Sucampo Pharmaceuticals’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.24 earnings per share.
A number of equities research analysts have commented on the stock. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. TheStreet cut shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Leerink Swann assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Monday, August 21st. They set an “outperform” rating and a $15.00 target price on the stock. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $16.50.
In related news, insider Jason Patrick Meyenburg acquired 4,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was acquired at an average cost of $12.13 per share, with a total value of $48,520.00. Following the acquisition, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Krensavage Asset Management LLC grew its holdings in Sucampo Pharmaceuticals by 0.6% during the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock valued at $29,607,000 after buying an additional 16,570 shares in the last quarter. LSV Asset Management grew its holdings in Sucampo Pharmaceuticals by 1.9% during the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock valued at $25,099,000 after buying an additional 44,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares in the last quarter. Finally, NEA Management Company LLC purchased a new stake in Sucampo Pharmaceuticals during the 2nd quarter valued at approximately $13,214,000. 55.46% of the stock is owned by institutional investors and hedge funds.
Shares of Sucampo Pharmaceuticals (SCMP) traded up 0.49% during trading on Tuesday, reaching $10.30. 45,589 shares of the company traded hands. The company’s 50-day moving average price is $11.46 and its 200-day moving average price is $10.69. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55. The company’s market capitalization is $477.15 million.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/brokerages-expect-sucampo-pharmaceuticals-inc-scmp-to-post-0-25-eps/1643688.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.